Aktana Announces First-To-Market GenAI Agents That Survive CRM Transitions
5.12.2024 16:00:00 CET | Business Wire | Press release
Aktana’s New Products Fortify Technology Stacks for the Future
Aktana, Inc., the leader in intelligent customer engagement for the global life sciences industry, today announced the Aktana Action Agent - designed to empower field teams and future-proof omnichannel engagement.
“The major players in Life Sciences CRM systems and Customer Data Platforms (CDPs) are changing roadmaps and partnerships, leaving pharma companies facing a serious innovation challenge.” said Derek Choy, Co-founder and Chief Product Officer of Aktana. “There’s an urgent need to help leaders find future-proofed solutions that address today’s business needs, as they confront expensive migration decisions in this shifting landscape.”
Aktana was recently named a Leader and one of only three Star Performers in the 2024 Life Sciences Next-Generation Customer Engagement Platform (CEP) PEAK Matrix® by Everest Group, cementing Aktana's position as a leading future-proof CEP.
“Life Sciences enterprises are increasingly prioritizing experience-driven Customer Engagement Platforms over traditional CRM systems, reflecting a significant shift towards customer-centric strategies,” said Chunky Satija, Vice President, Healthcare and Life Sciences, Everest Group.
Aktana Action Agent: Strategic Field Activity
Deeply integrated with Aktana’s Strategy Orchestration, Action Agent empowers life sciences teams to make smarter, data-driven decisions – harnessing the power of Large Language Models (LLMs). Purpose-built agents automate critical tasks such as:
1.) streamlining planning with suggested actions (forecasted to improve defined business outcomes);
2.) enabling pre-call preparation with insights tailored for each HCP;
3.) reducing logistical effort with automated call logging.
Faster Time-to-Value with CRM-Agnostic AI
Action Agent can be embedded into popular CRM systems like Veeva and Salesforce, giving customers optionality. Delivering immediate value on existing investments, Aktana ensures seamless migration so that customers are not locked into a siloed ecosystem.
Each agent is pre-configured so it can be deployed and scaled effortlessly, enabling customers to fill critical business gaps without migration delays. By providing a scalable and interoperable solution, Aktana Action Agent drives strategic alignment and delivers faster time-to-value for life sciences organizations.
Sign up for our webinar happening on Dec 12th to learn more about future-proof CRM strategies from our cofounder Derek Choy.
Learn more: Aktana Action Agent
About Aktana
Aktana provides AI-powered solutions tailored to the life sciences industry, enabling commercial teams to align strategies with customer needs, optimize engagement across channels, and deliver measurable impact.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205089781/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dominican Republic Drives Modernization of Electronic Passports Under the Leadership of the Thales - MIDAS Consortium25.3.2026 23:22:00 CET | Press release
The General Directorate of Passports, together with the Presidency of the Dominican Republic, are leading the transformation of the country’s passport issuance system with a new, secure, efficient document aligned with international standards.In 2025, the Thales-MIDAS consortium was awarded the contract to develop, issue, and personalize a modern, secure, and highly reliable travel document for Dominican citizens, incorporating additional cybersecurity measures. The Presidency of the Dominican Republic, through the General Directorate of Passports, issued the country’s first electronic passport as part of its strategy to modernize and strengthen national security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324368065/en/ Passport of the Dominican Republic The new document was developed in partnership with Thales, world leader in advanced technologies for the Defense, Aerospace, Cybersecurity, and Digital sectors, and M
3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 202625.3.2026 17:20:00 CET | Press release
Certification Marks Major Milestone in Strategic Dental Growth Initiative Addressing Straightening, Protection, Repair and Replacement of Teeth 3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026. This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers. The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Syst
Visa to Bring Privacy-Preserving Payments to Canton Network25.3.2026 17:00:00 CET | Press release
Visa is the first payments company selected to become a Super Validator on the Canton Network, where it will help banks and financial institutions bring new payment flows onchain Visa (NYSE:V), a global leader in digital payments, today announced it will join the Canton Network as the first major global payments company to serve as a Super Validator, to help extend privacy‑preserving blockchain infrastructure to banks and financial institutions around the world. Visa will be one of 40 Super Validators on Canton. That move goes straight to a core challenge for financial institutions: the same transparency that gives blockchains their appeal can clash with privacy expectations financial institutions operate under. Canton Network, a blockchain built for regulated finance, has privacy built in from the beginning, so organizations can use shared infrastructure without exposing sensitive information. As a Super Validator, Visa will help clients who choose to run and secure operations on the
ECU Worldwide Unveils XLERATE 2.0 Expansion to Bypass Asia–Europe Supply Chain Disruptions25.3.2026 14:30:00 CET | Press release
Strategic LAX gateway enables faster, predictable cargo movement through a reimagined sea–air logistics model ECU Worldwide, Allcargo Globals’ wholly-owned global subsidiary, has announced a strategic expansion of its transformative logistics solution, XLERATE 2.0, to provide a high-speed and resilient alternative to Asia-to-Europe trade lanes facing transit disruptions. Under this alternative routing, cargo is transported across the Pacific to the US West Coast, using Los Angeles (LAX) as a temporary hub. The solution leverages XLERATE 2.0’s premium, time-definite ocean services, ensuring greater transit agility and continuity. XLERATE 2.0 offers two distinct shipping solutions from China and Vietnam, providing shippers with flexibility as traditional trade arteries remain impacted by shifts in global logistics. These changes have led to reduced overall capacity and the disruption of standard sea–air services via conventional transit points. Commenting on the rollout, Simon Bajada, Re
Incyte Announces Executive Leadership Appointments25.3.2026 14:00:00 CET | Press release
Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive. Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing lat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom